CVF and HC3-1496 enhance the efficacy of monoclonal antibody therapy in vivo. Mice were inoculated intraperitoneally with 38C13 tumor cells on day 0. Select groups of mice were treated with antilymphoma IgG2a (MS11G6) on day 3, CVF on day 3 and day 5, or HC3-1496 on day 3 or day 5. (A) Survival of mice treated with MS11G6 alone, MS11G6 plus CVF, CVF alone, or untreated. (B) Survival of mice treated with MS11G6 alone, MS11G6 plus HC3-1496, HC3-1496 alone, or untreated (n = 10 mice per group)